In this webinar, Dr. Tom Snowden demonstrated why reduction methods are a potent and necessary tool in the modeler’s arsenal, how reduction methods can be applied to QSP models, and how model reduction can be used to extract scientific and business insights from complex models.
PRINCETON, NJ – July 25, 2017 – Certara today announced that Professor Piet van der Graaf, PharmD, PhD, vice president and head of Certara QSP, is co-chairing the NIH workshop entitled “QSP and Drug Discovery: Filling the Gaps in Current Models of the R&D Process for Neurotherapeutics.”
The eCTD struggle is real. Regulatory submissions must conform to the electronic common technical document (eCTD) format to be successfully received and reviewed by health authorities. And while this might seem simple, this complex technical process is actually rife with risk if you lack expertise in medical writing and regulatory publishing. In this blog post, … Continued
In helping clients with their regulatory operations and electronic publishing needs, I’m often asked about preparing regulatory submissions in the electronic common technical document (eCTD) format. While a lot of us have been working in the eCTD format for many years, new start-up companies focusing on rare diseases and new technologies to treat patients are … Continued
The pharmaceutical industry has long grappled with the problem of poorly written clinical study protocols. The study protocol describes the conduct of a study, its objectives, methodology, design, and statistical considerations and ensures the safety of participants and integrity of data collected. The teams generally responsible for protocol writing are the medical writing and regulatory … Continued
PRINCETON, NJ – July 13, 2017 – Certara today announced that Professor Jennifer B. Dressman, PhD, has been appointed to the Simcyp Scientific Advisory Board (SAB) to further strengthen its status in the biopharmaceutics field.
We recently completed a week-long set of meetings with the FDA, where we met with over 300 FDA reviewers from 7 of the 11 FDA centers that use Phoenix. Here are a few topics that took center-stage during our visits: Q: How can we create Phoenix workflow templates that are reusable across different studies with … Continued
